NeoGenomics Expands MRD Testing with RaDaR ST Launch
Event summary
- NeoGenomics launched RaDaR ST, a ctDNA assay for detecting molecular residual disease (MRD) in solid tumors.
- The test uses patient-specific, tumor-informed panels to detect tumor DNA in blood with a limit of detection at 95% probability (LOD95) of 11 ppm.
- RaDaR ST is validated through clinical and real-world data, including studies in breast and HPV-negative head and neck cancers.
- Medicare has approved initial launch indications, with two additional indications submitted for reimbursement.
The big picture
NeoGenomics' launch of RaDaR ST positions the company to capitalize on the growing demand for molecular residual disease testing, a largely untapped market. The test's ability to detect residual disease and recurrence sooner than conventional imaging aligns with broader industry trends toward earlier intervention and personalized cancer care. With Medicare approval for initial indications, NeoGenomics is poised to expand its comprehensive solid tumor care solution, potentially enhancing its competitive edge in the oncology diagnostics space.
What we're watching
- Market Adoption
- How quickly RaDaR ST will be integrated into clinical practice and research programs.
- Reimbursement Dynamics
- Whether the additional indications submitted for reimbursement will be approved and their impact on market penetration.
- Competitive Positioning
- The pace at which NeoGenomics can differentiate RaDaR ST in the rapidly growing MRD testing market.
Related topics